Information  X 
Enter a valid email address

Syncona Limited (SYNC)

  Print      Mail a friend

Thursday 25 June, 2020

Syncona Limited

Annual Financial Report

RNS Number : 1105R
Syncona Limited
25 June 2020

Syncona Limited

Publication of 2020 Annual Report and Notice of Annual General Meeting

25 June 2020

Syncona Ltd today announces that it has published its Annual Report and Accounts for the year ended 31 March 2020. In addition, Syncona has published its Notice of Annual General Meeting 2020.

In compliance with Listing Rule 9.6.1, these documents have today been submitted to the National Storage Mechanism and will shortly be available for inspection at .

Copies of these documents, together with the Form of Proxy for use in connection with the 2020 Annual General Meeting, are available electronically on Syncona's website at . Printed copies of these documents are also being posted to shareholders where requested.

Syncona's Annual General Meeting will be held at 10:30am on 28 July 2020 at the offices of Citco Fund Services (Guernsey) Limited, Arnold House, St Julian's Avenue, St Peter Port, Guernsey, GY1 3RD. Given the restrictions arising from the ongoing COVID-19 global pandemic, shareholders are strongly encouraged to ensure that their votes are counted at the 2020 Annual General Meeting by appointing the chair of the 2020 Annual General Meeting as their proxy in line with the procedures set out in the Notice of Annual General Meeting. 



Syncona Ltd

Siobhan Weaver / Annabel Clay 

Tel : +44 (0) 20 3981 7940


FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000


About Syncona

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t